197 related articles for article (PubMed ID: 11556844)
1. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity.
Galmarini CM; Falette N; Tabone E; Levrat C; Britten R; Voorzanger-Rousselot N; Roesch-Gateau O; Vanier-Viornery A; Puisieux A; Dumontet C
Br J Cancer; 2001 Sep; 85(6):902-8. PubMed ID: 11556844
[TBL] [Abstract][Full Text] [Related]
2. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells.
Jiang XH; Wong BC; Lin MC; Zhu GH; Kung HF; Jiang SH; Yang D; Lam SK
Oncogene; 2001 Nov; 20(55):8009-18. PubMed ID: 11753684
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
4. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.
Giannakakou P; Robey R; Fojo T; Blagosklonny MV
Oncogene; 2001 Jun; 20(29):3806-13. PubMed ID: 11439344
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T
Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860
[TBL] [Abstract][Full Text] [Related]
7. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
8. Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines.
Dey S; Spring PM; Arnold S; Valentino J; Chendil D; Regine WF; Mohiuddin M; Ahmed MM
Clin Cancer Res; 2003 Apr; 9(4):1557-65. PubMed ID: 12684432
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R
Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis.
Vikhanskaya F; Vignati S; Beccaglia P; Ottoboni C; Russo P; D'Incalci M; Broggini M
Exp Cell Res; 1998 May; 241(1):96-101. PubMed ID: 9633517
[TBL] [Abstract][Full Text] [Related]
11. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE
Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478
[TBL] [Abstract][Full Text] [Related]
12. Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells.
Ling YH; Zou Y; Perez-Soler R
Anticancer Res; 2000; 20(2A):693-702. PubMed ID: 10810342
[TBL] [Abstract][Full Text] [Related]
13. P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells.
Cui Q; Yu JH; Wu JN; Tashiro S; Onodera S; Minami M; Ikejima T
Acta Pharmacol Sin; 2007 Jul; 28(7):1057-66. PubMed ID: 17588343
[TBL] [Abstract][Full Text] [Related]
14. p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin.
Jaks V; Jõers A; Kristjuhan A; Maimets T
Oncogene; 2001 Mar; 20(10):1212-9. PubMed ID: 11313865
[TBL] [Abstract][Full Text] [Related]
15. Wild-type p53 induced sensitization of mutant p53 TNF-resistant cells: role of caspase-8 and mitochondria.
Ameyar-Zazoua M; Larochette N; Dorothée G; Daugas E; Haddada H; Gouloumet V; Métivier D; Stancou R; Mami-Chouaib F; Kroemer G; Chouaib S
Cancer Gene Ther; 2002 Mar; 9(3):219-27. PubMed ID: 11896437
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Bartussek C; Naumann U; Weller M
Exp Cell Res; 1999 Dec; 253(2):432-9. PubMed ID: 10585266
[TBL] [Abstract][Full Text] [Related]
17. Taxol induction of p21WAF1 and p53 requires c-raf-1.
Blagosklonny MV; Schulte TW; Nguyen P; Mimnaugh EG; Trepel J; Neckers L
Cancer Res; 1995 Oct; 55(20):4623-6. PubMed ID: 7553639
[TBL] [Abstract][Full Text] [Related]
18. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
Aranha O; Grignon R; Fernandes N; McDonnell TJ; Wood DP; Sarkar FH
Int J Oncol; 2003 Apr; 22(4):787-94. PubMed ID: 12632069
[TBL] [Abstract][Full Text] [Related]
19. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.
Galmarini CM; Clarke ML; Falette N; Puisieux A; Mackey JR; Dumontet C
Int J Cancer; 2002 Feb; 97(4):439-45. PubMed ID: 11802204
[TBL] [Abstract][Full Text] [Related]
20. A novel bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid carcinoma cells.
Juang SH; Pan WY; Kuo CC; Liou JP; Hung YM; Chen LT; Hsieh HP; Chang JY
Biochem Pharmacol; 2004 Jul; 68(2):293-303. PubMed ID: 15194001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
